TPV/r achieved a sustained virologic response, showed a good safety profile and was well tolerated at either dose. In pediatric patients with high baseline resistance profiles, high-dose TPV/r tended to demonstrate a better sustained response.
No takes yet. Share an insight, caveat, or question.
Salazar et al. (2008) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: